Efficacy and Safety of Intravenous Thrombolysis in the Extended Time Window for Acute Ischemic Stroke: A Systematic Review and Meta-Analysis
Эффективность и безопасность внутривенного тромболизиса в расширенном временно́м окне при остром ишемическом инсульте: систематический обзор и метаанализ
2025-08-04
SCID: 54.1/8jb7achb
Discuss with AI
acute ischemic strokeextended time windowintravenous thrombolysismodified Rankin Scalesymptomatic intracranial hemorrhage
Figures from the paper
Abstract (AI)
Background/Objectives: While intravenous thrombolysis (IVT) is the standard treatment for acute ischemic stroke (AIS) within 4.5 h of symptom onset, many patients present beyond this time window. Recent trials suggest that IVT may be both effective and safe in selected patients treated after the standard time window. Methods: We searched MEDLINE, Scopus, and ClinicalTrials.gov for randomized-controlled clinical trials (RCTs) and individual patient-data meta-analyses (IPDMs) of RCTs comparing IVT plus best medical treatment (BMT) to BMT alone in AIS patients who were last-known-well more than 4.5 h earlier. The primary efficacy outcome was a 90-day excellent functional outcome [modified Rankin Scale (mRS)-scores of 0–1]. Secondary efficacy outcomes included good functional outcome (mRS-scores 0–2) and reduced disability (≥1-point reduction across all mRS-strata). The primary safety outcome was symptomatic intracranial hemorrhage (sICH); secondary safety outcomes were any ICH and 3-month all-cause mortality. Subgroup analyses were performed stratified by different thrombolytics, time-windows, imaging modalities, and affected circulation. Results: Nine studies were included, comprising 1660 patients in the IVT-group and 1626 patients in the control-group. IVT significantly improved excellent functional outcome (RR = 1.24; 95%CI:1.14–1.34; I2 = 0%) and good functional outcome (RR = 1.18; 95%CI:1.05–1.33; I2 = 70%). IVT was associated with increased odds of reduced disability (common OR = 1.3; 95%CI:1.15–1.46; I2 = 0%) and increased risk of sICH (RR = 2.75; 95%CI:1.49–5.05; I2 = 0%). The rates of any ICH and all-cause mortality were similar between the two groups. No significant subgroup differences were documented. Conclusions: IVT in the extended time window improved functional outcomes without increasing mortality, despite a higher rate of sICH.
Key Findings
1
A systematic review and meta-analysis included nine studies with 1,660 IVT-treated and 1,626 control patients presenting beyond 4.5 hours after stroke onset.
2
Extended-window IVT increased symptomatic intracranial hemorrhage risk (RR 2.75, 95% CI 1.49–5.05), but rates of any intracranial hemorrhage and mortality were similar.
3
Extended-window intravenous thrombolysis significantly improved excellent functional outcome at 90 days (RR 1.24, 95% CI 1.14–1.34).
4
IVT also improved good functional outcome (RR 1.18, 95% CI 1.05–1.33) and overall disability reduction (common OR 1.30, 95% CI 1.15–1.46).
5
No significant subgroup differences were found across thrombolytic agents, treatment windows, imaging modalities, or affected circulation.
Research Object
Acute ischemic stroke patients treated with intravenous thrombolysis plus best medical treatment beyond the standard 4.5-hour window
Research Subject
The efficacy and safety of extended-window intravenous thrombolysis, including functional outcomes, disability reduction, symptomatic intracranial hemorrhage, and mortality
Publication Details
Publication Date
2025-08-04
Journal
Publisher
ISSN
Cited by
16
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai9
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews2021
Bias in meta-analysis detected by a simple, graphical test1997
RoB 2: a revised tool for assessing risk of bias in randomised trials2019
Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 20192021
Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association2019
Global, regional, and national burden of stroke and its risk factors, 1990–2021: a systematic analysis for the Global Burden of Disease Study 20212024
Tenecteplase for Ischemic Stroke at 4.5 to 24 Hours without Thrombectomy2024
Tenecteplase for Stroke at 4.5 to 24 Hours with Perfusion-Imaging Selection2024
Safety and efficacy of intravenous thrombolytic therapy in the extended window up to 24 hours: A systematic review and meta‐analysis2024